<DOC>
	<DOCNO>NCT02028117</DOCNO>
	<brief_summary>This study phase I/II open label clinical study patient platinum-resistant epithelial ovarian cancer . The Phase I part study determine dose enadenotucirev recommend study examine primarily safety tolerability also pharmacokinetics administer enadenotucirev intraperitoneally . Once dose IP enadenotucirev use combination IV weekly paclitaxel determine , phase II stage begin open label dose expansion regimen . The phase II stage aim determine whether intraperitoneal enadenotucirev risk benefit profile support investigation treatment patient platinum-resistant epithelial ovarian Cancer .</brief_summary>
	<brief_title>Phase I / Dose Expansion Study Enadenotucirev Ovarian Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>1 . Able willing provide write informed consent comply study protocol 2 . Age ≥ 18 year 3 . Histologically confirm nonresectable ovarian , fallopian tube primary peritoneal cancer 4 . Confirmed relapse within platinumresistant time frame . Platinumresistance define progression within 6 month receive prior platinumcontaining chemotherapy , progression identify either CT scanning ( RECIST v1.1 ) symptomatic CA125 progression ( GCIG CA125 criterion ) . The treatment immediately prior study entry need platinumbased . 5 . Measurable disease ( RECIST v1.1 ) . 6 . Able undergo intraperitoneal injection comply study procedure Investigator 's opinion 7 . Recovered least Grade 1 effect ( exclude alopecia ) prior therapy malignancy 8 . ECOG Performance Status Score 0 1 9 . Adequate renal function Creatinine ≤ 1.8 mg/dL calculate creatinine clearance use CockcroftGault formula ≥ 45 mL/min , measure creatinine clearance ≥ 45 mL/min , Absence clinically significant haematuria urinalysis : dipstick &lt; 2+ Absence clinically significant proteinuria urinalysis : dipstick &lt; 2+ . 10 . Adequate hepatic function serum bilirubin &lt; 1.5 x ULN AST ALT ≤ 3 x ULN 11 . Adequate bone marrow function : ANC ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , haemoglobin ≥ 90 g/L 12 . Adequate coagulation test : INR ≤ 1.5 x ULN ; 13 . Access archival tumour sample 14 . For female childbearing potential , negative pregnancy test must document prior enrolment ; 15 . For woman postmenopausal ( 12 month amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : agreement use two adequate method contraception , include least one method failure rate &lt; 1 % per year ( e.g. , hormonal implant , combine oral contraceptive , vasectomized partner ) , treatment period least 3 month last dose study drug ; 16 . For patient Phase II part study participate exploratory assessment tumour sample : Ovarian Disease amenable percutaneous imageguided biopsy . 1 . Tumours malignant mixed mesodermal ( MMMT ) mucinous subtypes , nonepithelial ovarian cancer ( e.g . Brenner tumour , Sexcord tumour ) . 2 . [ Criterion 2 remove current version protocol ] . 3 . Unresolved bowel obstruction ; 4 . Extensive intraabdominal adhesion / tumoural involvement small bowel 5 . Pregnant lactating ( nurse ) woman ; 6 . Known and/or history evidence significant immunodeficiency due underlie illness ( e.g . HIV/AIDS ) and/or medication ( e.g . systemic corticosteroid dose high dexamethasone 10 mg equivalent , immunosuppressive medication include cyclosporine , azathioprine , interferon , within past 4 week ) ; 7 . Splenectomy ; 8 . Prior allogeneic autologous bone marrow organ transplantation ; 9 . Active infection require antibiotic , physician monitoring , recurrent fever &gt; 38.0 degree centigrade associate clinical diagnosis active infection ; 10 . Active viral disease , positive serology HIV , hepatitis B hepatitis C ; 11 . Use follow antiviral agent : ribavirin , adefovir , lamivudine cidofovir within 7 day prior day 1 ; PEGIFN ( within 14 day prior day 1 ) ; 12 . Administration investigational drug within 28 day within 5 halflives first dose ColoAd1 , whichever longer . 13 . Administration systemic cancer therapy within 3 week first administration Coload1 14 . Major surgery within 3 week radiotherapy within 3 week prior first dose ColoAd1 ; 15 . Another primary malignancy within past 3 year ( except nonmelanoma skin cancer cervical cancer situ ) ; 16 . Known CNS metastasis ; 17 . Inflammatory disease bowel ; 18 . Concurrent congestive heart failure prior history New York Heart Association ( NYHA ) class III/IV cardiac disease . 19 . Any condition illness , opinion Investigator medical monitor , would compromise patient safety interfere evaluation safety drug ; 20 . Known allergy treatment medication excipients ; 21 . Any medical psychological condition would preclude participation study compromise ability give inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>